|
|
周德盈
Curriculum Vitae
|
Name
|
Teh-Ying Chou, MD, PhD, MBA
|
|
|
Title
|
Chair, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, TAIWAN
|
|
Address
|
No. 201, Sec. 2, Shipai Rd., Beitou District, Taipei City, 11217, TAIWAN
|
|
Email
|
tychou@vghtpe.gov.tw
|
|
Telephone
|
886-2-2875-7080, 7022
|
EDUCATION
|
2013-2016
1990-1995
|
EMBA
Ph.D.
|
International Business
Biochemistry, Cellular and Molecular Biology Training Program
|
National Taiwan University College of Management, Taiwan
Johns Hopkins University School of Medicine
(Thesis Advisors: Gerald W. Hart and Chi V. Dang)
|
|
1977-1984
|
M.D.
|
Medicine
|
National Yang-Ming University, Taiwan
|
POSTDOCTORAL TRAINING
|
2001-2002
1999-2001
|
Calendar Binford Clinical Fellow, Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology (Supervisor: William D. Travis)
Resident, Anatomic Pathology, Washington University Medical Center/Barnes-Jewish Hospital
|
POSITIONS AND APPOINTMENTS
Health Care Facility Appointments
|
2017-present 2012-2017
2006-2012
2004-2006
|
Chair, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taiwan
Chief, Molecular Pathology Division, Taipei Veterans General Hospital, Taiwan
Chief, Surgical Pathology Division, Taipei Veterans General Hospital, Taiwan
Chief, General Pathology Division, Taipei Veterans General Hospital, Taiwan
|
Academic Appointments
|
2018-present
2018-present
2013-2017
|
Professor, Brain Research Center, Tsing-Hua University
Professor, Department of Biotechnology and Laboratory Science in Medicine, Yang-Ming University
Director, Institute of Clinical Medicine, Yang-Ming University
|
|
2011-present
|
Professor, Institute of Clinical Medicine, Yang-Ming University
|
SCIENTIFIC AND MEDICAL SOCIETIES
Leadership Positions
|
2014-2017
2009-2014
|
President, Taiwan Society of Pathology / Taiwan Division of International Academy of Pathology
Chair, Molecular Pathology Committee, Taiwan Society of Pathology
|
Membership
|
2019-present
2014-present
|
Chair, Membership Committee, Pulmonary Pathology Society (PPS)
Member, Pathology Committee, International Association for the Study of Lung Cancer (IASLC)
|
EXPERTISE
Medicine, Biochemistry, Molecular Biology, Thoracic Pathology, Molecular Mechanisms of Tumor Metastasis, Precision Medicine
PBLICATIONS
Selected Publications since 2014: (* Corresponding Author)
- Yeh YC, Ho HL, Wu YC, Pan CC, Wang YC, Chou TY. AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma. Mod Pathol. 2019 Sep 16. [Epub ahead of print]
- Lin SC, Lin CH, Shih NC, Liu HL, Wang WC, Lin KY, Liu ZY, Tseng YJ, Chang HK, Lin YC, Yeh YC, Minato H, Fujii T, Wu YC, Chen MY,*Chou TY.* Cellular prion protein transcriptionally regulated by NFIL3 enhances lung cancer cell lamellipodium formation and migration through JNK signaling. Oncogene (2019) [Epub ahead of print]
- Ho HL, Kao HL, Yeh YC, Chou TY. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies. Diagn Pathol. 2019 Jun 21;14(1):59
- Chang WC, Yeh YC, Ho HL, Hsieh SL, Chou TY. Decoy Receptor 3 Expression Is Associated With Wild-Type EGFR Status, Poor Differentiation of Tumor, and Unfavorable Patient Outcome. Am J Clin Pathol. 2019 Jul 5;152(2):207-216
- Yeh YC, Kao HL, Lee KL, Wu MH, Ho HL, Chou TY. Epstein-Barr Virus-Associated Pulmonary Carcinoma: Proposing an Alternative Term and Expanding the Histologic Spectrum of Lymphoepithelioma-like Carcinoma of the Lung. Am J Surg Pathol. 2019 Feb;43(2):211-219.
- Kao HL, Yeh YC, Lin CH, Hsu WF, Hsieh WY, Ho HL,* Chou TY.* Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods. Lung Cancer (2016) 101:40-47
- Hung JJ,* Yeh YC, Jeng WJ, Wu KJ, Huang BS, Wu YC,* Chou TY,* Hsu WH.* Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival. Journal of Clinical Oncology (2014) 32(22)2357-2364
- Chiu CH, Ho HL, Chiang CL, Lin SF, Ma HH, Chuang YT, Lin KY, Tsai CM, Chou TY.* Clinical Characteristics and Treatment Outcomes of Lung Adenocarcinomas with Discrepant EGFR Mutation Testing Results Derived from PCR-Direct Sequencing and Real-Time PCR-Based Assays. Journal of Thoracic Oncology (2014) 9(1):91-96
BOOK CHAPTERS
1. Chou TY,* Cooper WA, Kerr KM. PD-L1 22C3 PharmDx Assay. In: Tsao MS, Kerr KM, eds. IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer, Editorial Rx Press, Aurora, Colorado 80011, USA, 2017; Chapter 5: 55-62
|
